Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
Ratings

Eternal Search

Heroes

People whose work, funding, scientific leadership, and multiplier effects have shaped the longevity field.

Every score here rates one thing: longevity commitment. The role tags — scientist, investor, founder, and the rest — describe what a person does. We do not compute a separate rating for each tag.

Scoring AI engine · v0.9.0

RolesAllcliniciancommunicatorentrepreneurinvestoroperatorphilanthropistpopulariserscientistself-experimenter
ThemesAllDestinationMeta ViewPathRisk ViewTimeline
SortOverallRecently updatedFuture visionScientific impactCapital deployedStrategic tasteField creationBravery and convictionMultiplier effect
#ScoreHeroDimensionsScored
164
Cynthia Kenyonv0.4.0
Kenyon helped prove aging is not mystical wear-and-tear: a single daf-2 mutation doubled worm lifespan. That result made genetic control of longevity a serious field, not a fringe wish.
scientistentrepreneuroperator
7/7263
George Churchv0.4.0
Church helped make longevity a genomics problem: aging-expression signatures, naked mole-rat transcriptomics, and screen pipelines. Not immortality dust; useful machinery.
scientistentrepreneurinvestor
7/7361
Marco Demariav0.8.0
Demaria helped define how senescent cells can aid wound healing yet drive age-related disease, then advanced their use as biomarkers and therapeutic targets.
scientistentrepreneur
6/7460
Alex Zhavoronkovv0.4.0
Zhavoronkov helped make AI drug discovery a serious longevity lane, not just conference vapor. His record is strongest in papers and Insilico’s aging-target work, not proven clinical wins.
populariserentrepreneurscientist
7/7560
João Pedro de Magalhãesv0.4.0
Magalhães helped build aging biology’s plumbing: genomic and longevity databases that became highly cited tools, not just another pile of anti-aging slogans.
scientistentrepreneurphilanthropist
7/7659
S. Jay Olshanskyv0.8.0
Olshansky shaped debates on longevity limits and made delayed aging a public-health and economic case. His 178 works have drawn more than 13,000 citations, including major papers on healthspan and life expectancy.
scientistentrepreneur
6/7758
Peter de Keizerv0.8.0
De Keizer helped establish targeted senescent-cell removal as a longevity strategy. His landmark 2017 paper has 1,456 citations, though human clinical benefit remains unproven.
scientistentrepreneur
6/7856
Matt Kaeberleinv0.4.0
Kaeberlein helped make mTOR, sirtuins, and rapamycin unavoidable in serious aging biology. Not a miracle salesman: his dog rapamycin trial found tolerability, not cardiac magic.
scientistpopulariserentrepreneur
7/7955
Andrea Maierv0.8.0
Andrea Maier has pushed geroscience toward clinical use through influential research on cellular senescence, sarcopenia and aging biomarkers. Her 747 papers have drawn 32,898 citations, with an h-index of 83.
scientistclinicianentrepreneur
6/71054
Laura Demingv0.4.0
Deming helped drag longevity biotech from weird sidebar into fundable company-building, then put her current bet on reversible organ cryopreservation. Not proof of victory; proof of taste.
investorentrepreneurpopulariser
7/71151
Juan Carlos Izpisua Belmontev0.4.0
Belmonte made cellular reprogramming a serious aging target, not a wellness slogan. His record includes 54,692 citations and major work on partial reprogramming of age-associated hallmarks.
scientistentrepreneur
7/71250
Eric Verdinv0.4.0
Verdin helped drag geroscience from aging folklore into citation-heavy biology: 73,392 citations, h-index 133, and major work on NAD+, sirtuins, inflammation, and aging biomarkers.
scientistentrepreneurinvestor
7/71350
Michael Levinv0.4.0
Levin gave longevity a less fashionable but useful target: tissue-level bioelectric control. His work treats aging partly as failed morphostasis, not just a pile of broken genes.
scientistentrepreneur
7/71449
Celine Haliouav0.8.0
Celine Halioua founded Loyal and raised $38 million to develop drugs that extend dogs’ lifespan and healthspan, with the aim of applying those lessons to human aging medicines.
entrepreneurscientist
7/71549
David Gobelv0.6.0
Gobel’s direct science record is thin. His real longevity impact is co-founding Methuselah Foundation, an early platform for prizes, grants, projects, and ventures chasing healthy lifespan.
philanthropistpopulariserentrepreneur
7/71649
Michael Grevev0.6.0
Greve helped make longevity more operational: Forever Healthy pushes intervention reviews and translation of molecular repair research into therapies. The capital claims are thinner than the legend.
investorphilanthropistentrepreneur
7/71749
Peter Fedichevv0.4.0
Fedichev pushed aging toward physics-style resilience models, not wellness fog. Through Gero and cited aging work, he helped make loss of resilience a testable longevity target.
entrepreneurscientist
7/71848
Nir Barzilaiv0.4.0
Barzilai helped drag longevity from supplement folklore toward testable geroscience: metformin, metabolic pathways, centenarians, and biomarkers. The citation trail is large; clinical proof is still the hard part.
scientistentrepreneurclinician
6/71948
Tony Wyss-Corayv0.8.0
Wyss-Coray advanced the study of how blood, immune cells, and microbiome metabolites shape brain aging, while developing biological clocks to measure aging across organs and guide healthspan research.
scientistentrepreneur
6/72047
Daisy Robintonv0.8.0
Robinton co-founded Oviva to develop drugs that preserve ovarian function and extend women’s healthspan. Its lead program targets ovarian response, but clinical benefit has not been shown.
entrepreneur
6/72147
Emil Kendziorrav0.4.0
Kendziorra helped move biostasis from fringe talk into actual institutions and research roadmaps. The science is still speculative; the operator work is the real signal.
entrepreneurscientistself-experimenter
7/72246
Kristen Fortneyv0.4.0
Fortney helped drag aging biology toward drug development: BioAge plus 50 papers, 1,614 citations, and work on aging biomarkers and drug networks. Not a miracle claim; a real translational footprint.
entrepreneurscientist
7/72344
Jim Mellonv0.4.0
Mellon helped make longevity biotech legible as a company category, mainly through Juvenescence and field-definition papers. Scientific footprint: modest, not mythical.
entrepreneurinvestorphilanthropist
7/72443
Michael D. Westv0.4.0
West helped drag longevity from supplement folklore toward cell biology: telomerase, cell immortality, cloning, and embryonic stem-cell derivatives. Human life-extension proof is not there.
scientistentrepreneur
7/72541
Anar Ismanv0.4.0
Isman’s impact is practical, not mythic: AgelessRx-linked studies put off-label rapamycin, LDN/NAD+, and QoL endpoints into real-world longevity data. Useful work; not field conquest.
entrepreneurscientistinvestor
7/72640
Bryan Johnsonv0.4.0
Johnson made longevity louder by turning his own protocol into media, a Don’t Die campaign, and an Rx platform. The hard evidence for field-building or scientific impact is thin.
self-experimenterpopulariserentrepreneur
7/72740
James Peyerv0.8.0
Peyer founded Cambrian Bio to turn aging biology into a portfolio of medicines. He also coauthored papers defining longevity biotech and proposing shared biomarker practices for trials.
entrepreneurscientist
7/72840
Kai Micah Millsv0.4.0
Mills has pushed longevity toward cryonics infrastructure, not wellness theater, by building Cryopets and CryoDAO and publicly framing death as a technical problem. Evidence is thin; this is movement-building, not proven impact yet.
entrepreneurpopulariserinvestor
7/72940
Nathan Chengv0.4.0
Cheng helped give longevity’s speculative edge an address: co-founding Longevity Biotech Fellowship and co-authoring a 2024 biostasis roadmap. The science is early; the agenda is concrete.
populariserentrepreneurinvestor
7/73039
David Sinclairv0.4.0
Sinclair helped push longevity toward testable aging biology, including work on sex- and tissue-specific gene expression in aging mice. The company-founder story is thinner, so don’t gild it.
scientistentrepreneurpopulariser
7/73137
Jean Hébertv0.4.0
Hébert gave brain aging a harder target than pills: progressive cell replacement. In mice, his FGF work also showed old hippocampal neurogenesis could be restored to young-adult levels.
scientistentrepreneur
6/73236
Joe Betts-LaCroixv0.8.0
Betts-LaCroix helped define longevity biotechnology and co-authored guidance for bringing aging biomarkers into clinical research. His five papers have received 198 citations.
entrepreneurscientist
7/73334
Martin Borch Jensenv0.4.0
Jensen helped make mitochondrial aging less hand-wavy: 76 works, 1,955 citations, and longevity org-building through Gordian and Norn. Real contribution, not life-extension magic.
entrepreneurphilanthropistpopulariser
7/73433
Christian Angermayerv0.6.0
Angermayer’s impact is publicity, not proven geroscience. He helped drag longevity-adjacent human enhancement into public markets, sports spectacle, and telehealth. Messy, but visible.
entrepreneurinvestorself-experimenter
6/73532
Kelsey Moodyv0.8.0
Moody co-authored research linking stronger SIRT6-driven DNA repair to longer-lived species. He also helped show that C60 in olive oil failed to extend mouse lifespan and became toxic under ambient light.
entrepreneurscientist
7/73630
Peter Diamandisv0.4.0
Diamandis helped push longevity toward AI-led health tracking and company-building, not lab-defining science. The evidence shows one aging-clock paper with 29 citations and thin disclosed capital.
entrepreneurpopulariserinvestor
7/73730
Phil Newmanv0.4.0
Phil Newman’s longevity impact is translation, not miracle-making: he built longevity media platforms and brings a modest scientific record, with h-index 19 and 1,438 citations.
populariserentrepreneurcommunicator
7/73830
Yuri Milnerv0.4.0
Milner is weakly linked to Altos Labs, making his visible longevity impact a reported bet on cellular reprogramming rather than a proven field record. Thin evidence, so no victory lap.
philanthropistinvestorentrepreneur
6/73924
Omri Droryv0.4.0
Drory helped frame longevity as techbio infrastructure work, not wellness theater: measure biology better, then pursue reprogramming, regeneration, and replacement. Evidence is thin; call this a signal, not proven field impact.
investorentrepreneurself-experimenter
7/74010
Jacob Hannav0.4.0
Hanna’s supported longevity footprint is thin: stem-cell scientist, coauthor on a 2025 aging-biology workshop paper. That links him to the field, not to a proven life-extension program.
scientistentrepreneur
6/7